American Journal of Cardiology
Volume 106, Issue 6 , Pages 764-769 , 15 September 2010

Relation of Elevated Plasma Renin Activity at Baseline to Cardiac Events in Patients With Angiographically Proven Coronary Artery Disease

  • Joseph B. Muhlestein, MD

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah
    • Corresponding Author InformationCorresponding author: Tel: (801) 507-4701; fax: (801) 507-4789
    • ,
  • Heidi T. May, PhD

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • ,
  • Tami L. Bair, BS

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • ,
  • Margaret F. Prescott, PhD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
    • ,
  • Benjamin D. Horne, PhD

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah
    • ,
  • Richard White, PhD

      Affiliations

    • Research Evaluation Unit, Oxford PharmaGenesis Ltd., Oxford, United Kingdom
    • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • Intermountain Medical Center, Murray, Utah
    • University of Utah, Salt Lake City, Utah

Received 21 January 2010 ,Revised 23 April 2010

References 

  1. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441–449
  2. Blumenfeld JD, Sealey JE, Alderman MH, Cohen H, Lappin R, Catanzaro DF, et al. Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. Am J Hypertens. 2000;13:855–863
  3. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10:1–8
  4. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292–299
  5. Vergaro G, Fontana M, Poletti R, Giannoni A, Iervasi AL, Masi L, et al. Plasma renin activity is an independent prognostic factor in chronic heart failure (abstract). Eur Heart J. 2008;29(Suppl 1):393
  6. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583–591
  7. Verma S, Gupta M, Holmes DT, Teoh H, Xu L, Yusuf S, et al. Plasma renin activity is associated with increased cardiovascular events and mortality in the HOPE study (abstract). Circulation. 2009;120:S453
  8. Fung JW, Yu CM, Yip G, Chan S, Yandle TG, Richards AM, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol. 2003;92:406–410
  9. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst. 2009;10:65–76
  10. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663–1671
  11. Ronnow BS, Reyna SP, Muhlestein JB, Horne BD, Allen Maycock CA, Bair TL, et al. C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. Cardiology. 2005;104:196–201
  12. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492–2499
  13. Lijnen P, Fagard R, Staessen J, Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol. 1981;12:387–392
  14. Colantonio D, Casale R, Desiati P, Giandomenico G, Bucci V, Pasqualetti P. Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension. J Clin Pharmacol. 1991;31:238–242

 This study was supported by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

 Dr. Muhlestein has served on speakers' bureaux for Bristol-Myers Squibb, GSK, Merck, Novartis, and Sanofi-Aventis. Dr. Prescott is an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and is thus eligible for Novartis stock and stock options. Dr. White is an employee of Oxford PharmaGenesis Ltd., which has received project funding from Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

PII: S0002-9149(10)01036-2

doi: 10.1016/j.amjcard.2010.04.040

American Journal of Cardiology
Volume 106, Issue 6 , Pages 764-769 , 15 September 2010

Article Tools

* Image Usage & Resolution